Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte 56 and Dextrose 5% is a crystalloid solution that provides electrolytes and carbohydrates. Dextrose is metabolized to glucose, which is utilized for cellular energy production. The electrolytes (sodium, chloride, potassium, magnesium, and acetate) maintain or restore intravascular volume, acid-base balance, and osmotic gradients. Acetate is metabolized to bicarbonate, providing an alkalinizing effect.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Intravenous infusion for fluid and electrolyte replacement in patients with mild to moderate fluid loss,Source of calories (dextrose) and electrolytes,Maintenance of hydration and electrolyte balance,Treatment of metabolic acidosis (alkalinizing effect from acetate),Off-label: Use as a vehicle for drug administration
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Intravenous infusion; dose depends on fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, rate up to 333 m L/hour. Maximum 3 L/24 hours.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Not applicable; composition-dependent. Dextrose half-life ~2 hours. Electrolytes follow endogenous regulation; no terminal elimination half-life defined.
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Dextrose is metabolized via glycolysis and the Krebs cycle. Acetate is metabolized in the liver and peripheral tissues to bicarbonate. Electrolytes are not metabolized.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Renal 100% (electrolytes and dextrose metabolized to CO2 and water; excess water and electrolytes excreted unchanged in urine).
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
<5% (minimal; free ions and glucose).
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
0.2-0.3 L/kg (dextrose and electrolytes distribute primarily in extracellular fluid; total body water for water).
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Intravenous: 100%.
Intravenous: 100%.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload. For GFR 30-60 m L/min: monitor potassium and fluid status closely; reduce infusion rate and volume.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
Use with caution in severe hepatic impairment (Child-Pugh C) due to risk of fluid overload and electrolyte imbalances. No specific dose adjustment defined; monitor closely.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Weight-based: 20-40 m L/kg per dose as a single infusion, rate not to exceed 10 m L/kg/hour. For maintenance: 100-150 m L/kg/day, adjusted for age and clinical status.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Use with caution due to decreased renal function; consider baseline GFR. Reduce rate and total volume to avoid fluid overload. Monitor electrolytes and volume status frequently.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
None
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Use with caution in patients with renal impairment, heart failure, or conditions with fluid overload,Risk of electrolyte disturbances (hyperkalemia, hypermagnesemia, hypernatremia) with excessive or rapid infusion,May cause hyperglycemia in patients with diabetes mellitus or glucose intolerance,Avoid in patients with severe metabolic acidosis without adequate buffering capacity,Monitor serum electrolytes, glucose, fluid balance, and acid-base status during prolonged therapy,Not recommended for use in neonates or pediatric patients with significant renal impairment due to potassium content
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Hyperkalemia,Hypernatremia,Severe renal failure with oliguria or anuria,Severe metabolic acidosis (e.g., lactic acidosis, diabetic ketoacidosis),Concurrent administration of medications that may exacerbate hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors),Patients with known allergy to any component
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
No dietary restrictions are required. However, this solution contains dextrose, which may affect blood glucose; diabetic patients should monitor carbohydrate intake accordingly. No known food interactions.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
First trimester: No known teratogenic effects. Dextrose and electrolytes are physiological components; no structural anomalies reported. Second and third trimesters: No fetal risk; used for fluid and electrolyte maintenance. High dextrose concentrations may cause maternal hyperglycemia, potentially leading to fetal hyperinsulinemia and neonatal hypoglycemia if infused rapidly or in large volumes.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Dextrose and electrolytes are normal constituents of breast milk. No adverse effects expected. M/P ratio not applicable as components are endogenous.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
No dose adjustment needed for pregnancy-specific pharmacokinetic changes. However, the increased blood volume and glomerular filtration rate may necessitate faster infusion rates to maintain adequate volume; caution to avoid fluid overload. Dextrose infusion rate should be adjusted to maintain maternal blood glucose < 130 mg/d L to prevent fetal hyperinsulinemia.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
PLASMA-LYTE 56 AND DEXTROSE 5% is an isotonic solution containing electrolytes and a low dextrose concentration (5 g/d L). It provides 170 m Osm/L, making it hypotonic relative to plasma. Use cautiously in patients with increased risk of hyponatremia or cerebral edema (e.g., children, elderly, post-op). Co-administration of dextrose may cause hyperglycemia; monitor blood glucose in diabetics. Not for use as a sole source of calories; dextrose concentration insufficient for nutritional support. Contraindicated in patients with hyperkalemia, hypercalcemia, or severe lactic acidosis. Do not administer if solution is discolored or contains particulates.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
This intravenous solution provides fluids, sugar, and electrolytes to maintain hydration and balance.,Tell your healthcare provider if you have diabetes, kidney disease, heart failure, or electrolyte disorders.,Report any symptoms like headache, nausea, confusion, or swelling during infusion.,This solution is given through a vein; do not adjust the flow rate yourself.,If you experience pain, redness, or swelling at the infusion site, notify your nurse immediately.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte 56 and Dextrose 5% is a crystalloid solution that provides electrolytes and carbohydrates. Dextrose is metabolized to glucose, which is utilized for cellular energy production. The electrolytes (sodium, chloride, potassium, magnesium, and acetate) maintain or restore intravascular volume, acid-base balance, and osmotic gradients. Acetate is metabolized to bicarbonate, providing an alkalinizing effect.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, rate up to 333 m L/hour. Maximum 3 L/24 hours.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. First trimester: No known teratogenic effects. Dextrose and electrolytes are physiological components; no structural anomalies reported. Second and third trimesters: No fetal risk;. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.